Veracyte, Inc. (VCYT)

Veracyte: Q4 Earnings Insights

Shares of Veracyte (NASDAQ:VCYT) were unchanged in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 6.67% over the past year to ($0.14), which missed the estimate of ($0.11). Revenue of $34,536,000 up by 16.17% year over year, which beat the estimate of $31,930,000. Guidance Veracyte Sees FY21 Sales $190M-$200M Vs. $151.18M Est. Conference Call Details Date: Feb 17, 2021 Time: 05:30 PM View more earnings on VCYT ET Webcast URL: https://edge.media-server.com/mmc/p/p7geixt9 Price Action 52-week high: $86.03 Company's 52-week low was at $13.90 Price action over last quarter: Up 93.62% Company Profile Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others. The company derives its revenues from the Sale of Afirma analysis product. See more from BenzingaClick here for options trades from BenzingaEarnings Scheduled For February 17, 2021Earnings Outlook For Veracyte© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.